Mediplantex National Pharmaceutical

What Mediplantex National Pharmaceutical does

Mediplantex National Pharmaceutical Joint Stock Company (HNX: MED) is a Vietnamese pharmaceutical manufacturer founded in 1958 and headquartered at 358 Giải Phóng, Hanoi. The company produces both traditional Eastern medicine (Đông Dược) and modern medicine (Tân Dược) across multiple dosage forms including tablets, capsules, syrups, powders, and oral solutions, operating from a network of three facilities in the Hanoi region: Factory 1 / headquarters on Giải Phóng Street, Factory 2 at Mê Linh (20,000m² site with 700-800 million units/year capacity and a 10,000m² GSP-standard warehouse), and Factory 3 under construction at the Hòa Lạc High-Tech Industrial Park with a 1,200 billion VND investment across 4 hectares.

The company's core technology is GMP-certified pharmaceutical manufacturing backed by two GLP-standard quality control rooms, a 2,000m² GMP dược liệu (herbal) workshop, and an HS-GMP health food production line. The product portfolio spans analgesics (Paracetamol family), antibiotics (Acyclovir, Clinecid, Neazi), gastrointestinal medications (Omeprazol, Melankit), anti-inflammatories (Dilovic, Epfepara codein), mucolytics (Mycomuc), hemostatics (Medisamin), and supplements (Biotin, Admed, Metid, Medikids, Siro Limcee), as well as traditional Vietnamese remedies (Dũ Thương Linh). Pricing is not publicly disclosed; products are sold through direct inquiry.

Mediplantex operates a sales-led go-to-market model, distributing domestically through Vietnamese pharmacy and hospital networks while pursuing international expansion via an Alibaba.com B2B export partnership and the K-MEDI Silk Road consortium spanning seven Asian countries. Revenue streams include pharmaceutical manufacturing and domestic sales, import/export of raw materials and finished goods, and B2B e-commerce exports. The company became publicly listed on the Hanoi Stock Exchange in March 2020 and reports annual revenue in the multi-trillion VND range with growing net income. The customer base is diversified across domestic healthcare buyers and international B2B channels, with no single customer concentration disclosed.

Name

Mediplantex National Pharmaceutical

Legal name

Công ty Cổ phần Dược Trung ương Mediplantex

Website

https://mediplantex.com

Company type

Public

Founded year

1958

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Mediplantex National Pharmaceutical is a Vietnamese manufacturer (HNX: MED) producing both Eastern (Đông Dược) and modern (Tân Dược) medicines across multiple dosage forms, serving domestic pharmacies, hospitals, and international B2B export markets through GMP-certified facilities in Hanoi.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Traditional herbal medicine
• Generic medicine production
• Tablet and capsule production
• Pharmaceutical distribution

Headquarters

HQ city

Hanoi

HQ country

Vietnam

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing and Sales: Manufacturing and domestic sales of pharmaceutical products including Eastern medicine (Đông Dược) and modern medicine (Tân Dược) across multiple dosage forms (tablets, capsules, syrups, powders, oral solutions). Products sold domestically through pharmacy and healthcare distribution networks.
2. Import/Export of Pharmaceutical Materials: Import and export of raw materials, pharmaceutical ingredients, finished goods, medical devices, and fragrances.
3. B2B E-commerce Export: Export of pharmaceutical and health products through Alibaba.com B2B platform for international market expansion.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Mediplantex is a Vietnamese pharmaceutical manufacturer that produces and sells both traditional Eastern herbal medicine (Đông Dược) and modern Western medicine (Tân Dược). Its product range spans multiple dosage forms including tablets, capsules, syrups, oral solutions, powders, and topical preparations, manufactured in GMP-certified facilities and distributed through domestic pharmacies, hospitals, and B2B export channels.

Product overview

Mediplantex National Pharmaceutical is a Vietnamese pharmaceutical company that manufactures and distributes a diverse portfolio of pharmaceutical products and traditional medicines. The product portfolio includes modern pharmaceuticals such as analgesics (Paracetamol, Dilovic), antibiotics (Acyclovir, Clinecid, Neazi), gastrointestinal medications (Omeprazol, Melankit), and vitamins/supplements (Biotin, Admed, Metid), as well as traditional Vietnamese medicines (Dũ Thương Linh). The company operates multiple manufacturing facilities including GMP-certified plants for producing various dosage forms including tablets, capsules, and syrups.

Differentiator

Problem solved

Functional benefit

Products and services

• MediClary Pharmaceutical product from Mediplantex's branded portfolio.
• Siro Limcee Syrup product in Mediplantex's portfolio of liquid dosage forms.
• A.T.P Pharmaceutical product from Mediplantex's branded medicine portfolio.
• Acyclovir 200 Antiviral medicine (acyclovir 200 mg) in Mediplantex's modern medicine portfolio for the treatment of viral infections.
• Admed Pharmaceutical product from Mediplantex's branded portfolio.
• Biotin Biotin supplement/vitamin product in Mediplantex's portfolio.
• Clinecid 300 mg Antibiotic medicine (clindamycin 300 mg) from Mediplantex's modern medicine portfolio.
• Neazi 500 mg oral suspension powder Cốm pha hỗn dịch Neazi 500 mg — oral suspension powder dosage form from Mediplantex.
• Dilovic 7.5 mg Pharmaceutical product (7.5 mg dosage) from Mediplantex's portfolio.
• Doxmin Pharmaceutical product from Mediplantex's branded portfolio.
• Dũ Thương Linh Traditional Eastern medicine (Đông Dược) product from Mediplantex's traditional medicine portfolio.
• Epfepara codein Codeine-containing pharmaceutical product from Mediplantex's modern medicine portfolio.
• Medikids Pediatric pharmaceutical product from Mediplantex's portfolio targeting children.
• Medisamin 250 mg Pharmaceutical product (250 mg dosage) from Mediplantex's portfolio.
• Medisamin 500 mg Pharmaceutical product (500 mg dosage) from Mediplantex's portfolio.
• Melankit Pharmaceutical product from Mediplantex's portfolio.
• Metid Pharmaceutical product from Mediplantex's portfolio.
• Mycomuc Pharmaceutical product from Mediplantex's portfolio.
• Omeprazol Gastrointestinal medicine (omeprazole) from Mediplantex's modern medicine portfolio.
• Paracetamol 325 mg Analgesic/antipyretic paracetamol 325 mg product from Mediplantex's portfolio.
• Paracetamol 500 mg Analgesic/antipyretic paracetamol 500 mg product from Mediplantex's portfolio.
• Paracetamol 650 mg Analgesic/antipyretic paracetamol 650 mg product from Mediplantex's portfolio.
• Penveril Pharmaceutical product from Mediplantex's portfolio.

Quantifiable outcome

• Revenue exceeding 700 billion VND in 2018 with nearly 40 billion VND after-tax profit

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Trường Đại học Daegu Haany (Korea)coreStrategic or Co-development Partner · 19 February 2025Bilateral cooperation meeting between Mediplantex, University of Health Sciences, and Daegu Haany University (Korea) under the K-MEDI Silk Road framework. Discussions focused on herbal medicine development from Vietnam's endemic species, regulatory harmonization, and exchange programs including short-term training and postgraduate scholarships.
• Trường Đại học Khoa học Sức khỏe, ĐHQG-HCMcoreStrategic or Co-development Partner · 19 February 2025Joint working session with Mediplantex and Daegu Haany University to advance traditional medicine research and development cooperation. Focused on herbal medicine product development, regulatory alignment, training exchange, and postgraduate scholarship programs.
• K-MEDI Silk Road Project ConsortiumcoreStrategic or Co-development Partner · 18 December 2024International consortium promoting traditional medicine research, education, and industry development across Vietnam, Mongolia, Uzbekistan, Turkey, Kyrgyzstan, Thailand, and Korea. Mediplantex participates as a leading Vietnamese pharmaceutical manufacturer committed to R&D cooperation, herbal product development, and training programs for traditional medicine professionals.
• Alibaba.comcoreGTM or Marketing Partner · 10 June 2024Partnership with the world's leading B2B e-commerce platform Alibaba.com for online export of Vietnamese pharmaceutical and health products. The goal is to connect and support Vietnamese manufacturing enterprises in online export operations, expanding reach to global buyers through B2B e-commerce channels.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Pymepharco: Pymepharco (HOSE: PME) is a Vietnamese pharmaceutical manufacturer producing generic and branded medicines. Direct peer to Mediplantex in scale, product portfolio, and domestic Vietnamese market focus.
• Traphaco: Traphaco (HOSE: TRP) is a leading Vietnamese pharmaceutical manufacturer with strong positioning in traditional/herbal medicines alongside modern drugs. Closely comparable to Mediplantex's dual Đông Dược and Tân Dược manufacturing model and export ambitions.
• DHG Pharmaceutical: DHG Pharmaceutical (HOSE: DHG) is one of Vietnam's largest pharmaceutical manufacturers, producing prescription drugs, OTC medicines, and supplements across multiple dosage forms. Directly comparable to Mediplantex as a domestic Vietnamese pharma manufacturer with parallel GMP infrastructure and a similar broad product portfolio.
• Domesco Medical Import Export: Domesco (HOSE: DMC) is a Vietnamese pharmaceutical manufacturer producing prescription and OTC drugs across multiple dosage forms. Direct peer of Mediplantex in domestic Vietnamese manufacturing with a comparable product mix and distribution footprint.
• Mekophar Chemical Pharmaceutical: Mekophar (HOSE: MKP) is a Vietnamese pharmaceutical manufacturer with broad portfolio across multiple dosage forms. Comparable to Mediplantex as a domestic pharma manufacturer competing in the same Vietnamese market channels.
• Imexpharm Pharmaceutical: Imexpharm (HOSE: IMP) manufactures and distributes pharmaceutical products in Vietnam with a focus on generic and branded drugs. Direct peer to Mediplantex in domestic Vietnamese pharma manufacturing with overlapping product categories.
• Stellapharm (STADA Vietnam): Stellapharm is the Vietnamese manufacturing joint venture of Germany's STADA, producing generic pharmaceuticals in Vietnam. Directly comparable to Mediplantex in generic drug manufacturing and GMP-certified Vietnamese production capacity.
• OPC Pharmaceutical: OPC Pharmaceutical (HOSE: OPC) is a Vietnamese pharmaceutical manufacturer with notable strength in traditional herbal/Đông Dược medicines. Directly comparable to Mediplantex, particularly in the herbal medicine segment and domestic Vietnamese distribution.

Broad incumbents

• Bayer Vietnam: Bayer Vietnam is the local entity of global pharmaceutical major Bayer, distributing prescription drugs, OTC products, and consumer health across Vietnam. Comparable to Mediplantex in the Vietnamese pharmaceutical market but with a global brand portfolio and broader therapeutic coverage.
• Sanofi Vietnam: Sanofi Vietnam is the local entity of global pharmaceutical company Sanofi, distributing prescription drugs, vaccines, and consumer health products in Vietnam. Comparable to Mediplantex in the Vietnamese prescription/OTC market but as a multinational with broader portfolio and global R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@congtycpduoctwmediplantex4672
• Facebookfacebook.com/mediplantex

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediplantex National Pharmaceutical